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ti-TNF? The main justification of immunosuppressant mono-
therapy is the low cost of this treatment and the possibility 
of achieving a very stable and long-standing remission in a 
subset of patients. According to this and provided there is no 
rapid need for more effective therapy, this treatment could 
be tried in any inflammatory bowel disease patient not cor-
rectly maintained after a course of steroids and 5-aminosali-
cylic acid. However, the failure to respond to this treatment 
should be recognized early and a step up to anti-TNF consid-
ered. An anti-TNF treatment should be considered early in 
patients at risk of rapid evolution towards tissue damage 
and complications. The benefit/risk of the immunosuppres-
sant + anti-TNF combination therapy should be assessed on 
a case-by-case basis. Anti-TNF treatment should always be 
fully optimized by adapting dosage and potentially adding 
an immunosuppressant before considering treatment fail-
ure. Treatment de-escalation should only be considered 
when a long-standing stable remission has been achieved 
both clinically and biologically. The cost sparing and theo-
retical decrease in complication risk should be put in per-
spective with the risk of relapse and disease progression. 
 © 2013 S. Karger AG, Basel 
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 Abstract 
 Controlled trials and meta-analyses have shown that immu-
nosuppressants are effective in steroid-dependent Crohn’s 
disease (CD) and, although less well demonstrated, ulcera-
tive colitis (UC). It has also been demonstrated that anti-TNF 
are effective in steroid-dependent and steroid-refractory CD 
and UC. Anti-TNF can also decrease hospitalization rate and 
the need for surgery. This seems also to be the case for im-
munosuppressants. The early use of anti-TNF seems more 
effective than later use, and early mucosal healing is associ-
ated with decreased rate of surgery. On the contrary, early 
use of purine analogues does not seem to improve outcome 
in CD. Anti-TNF therapies have been shown superior to im-
munosuppressants and combination therapy superior to an-
ti-TNF monotherapy in inducing steroid-free remission and 
mucosal healing. The main strategic questions which remain 
at this stage include: When to start immunosuppressants or 
anti-TNF? Is there still a place for immunosuppressant mono-
therapy? How to optimize anti-TNF? Is it possible to stop an-
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 Anti-TNF monoclonal antibodies are effective for the 
treatment of moderate to severe Crohn’s disease (CD)  [1–
3] and ulcerative colitis (UC)  [4, 5] . Meta-analyses and 
randomized controlled trials have also shown efficacy of 
purine analogues and methotrexate for the treatment of 
CD  [6, 7] . The efficacy of purine analogues for UC is less 
well established, although a recent meta-analysis also sug-
gests its superiority over placebo  [8] . The efficacy of 
methotrexate in UC has not been adequately studied yet. 
 CD is now considered a progressive disease character-
ized by tissue damage accumulation leading to surgical 
resections and disability  [9] . Anti-TNF and to a lesser ex-
tent immunosuppressants are able to heal the mucosa and 
to prevent surgical resection  [10, 11] . This ability, which 
had not been demonstrated for steroids or mesalazine, 
makes these drugs the cornerstones of maintenance treat-
ment of CD aiming at achieving sustained and deep re-
mission. Nevertheless, natural history of CD is very het-
erogeneous and, according to population-based data, up 
to half of the patients may have a benign course of the 
disease and may thus not justify the use of immunosup-
pressants or anti-TNF antibodies  [12] .
 Evidence for a progressive nature of UC is less striking, 
particularly because penetrating and stricturing lesions 
are not occurring, and because surgery is seen as a unique 
step that may to some extent cure the patient. Neverthe-
less, the risk of colorectal cancer due to chronic uncon-
trolled mucosal inflammation  [13] and the mucosal fi-
brosis leading to colonic and rectal loss of compliance are 
examples of long-term tissue damage in this disease  [14] . 
Mesalazine and steroids are more effective in UC than
in CD, particularly to achieve mucosal healing  [15, 16] . 
Therefore, immunosuppressants and anti-TNF are really 
reserved here for patients not adequately responding to 
these drugs.
 Both in CD and UC, immunosuppressants and anti-
TNF may induce significant side effects, sometimes se-
vere, including infections and neoplasia  [17, 18] . For this 
reason, as well as due to the cost of anti-TNF treatments, 
the benefit/risk and the benefit/cost of these treatments 
should be rigorously and regularly assessed during the 
disease course.
 The most important questions that are still pending for 
the strategic use of immunosuppressants and anti-TNF in 
inflammatory bowel disease (IBD) include the following: 
when to start these drugs? Should one use them as mono-
therapy or combination therapy? Is it possible to stop 
these treatments?
 When to Start Immunosuppressants or Anti-TNF in 
IBD? 
 Post-hoc analyses of several clinical trials with anti-TNF 
in CD have shown a higher efficacy to induce remission or 
mucosal healing when the treatment was started earlier in 
the disease  [19, 20] . However, this has not been demon-
strated in UC yet. The situation is more difficult to inter-
pret for immunosuppressants. The ability of these drugs
to change natural history and particularly to decrease the 
need for surgical resection in CD has been assessed in dif-
ferent studies with controversial results  [21–23] . One rea-
son for these controversial results may be the timing of the 
introduction of immunosuppressants, a therapy started 
too late being unable to impact on this surgical rate. Nev-
ertheless, a recent GETAID study specifically evaluating 
the question of early introduction of azathioprine in CD 
patients with a high theoretical risk of developing disabling 
disease did not show early introduction to be superior to 
later more classical introduction of the drug  [24] . 
 According to these data, the optimal timing of immu-
nosuppressant or anti-TNF therapy may thus be difficult 
to determine. We propose to schematically split IBD into 
three big categories depending on their natural history: 
the benign disease which may represent in population-
based studies up to half of the patients  [12] , the directly 
severe disease which may represent one fifth of the pa-
tients and the secondarily severe diseases which represent 
the last third of the patients. In the first category of pa-
tients, there is no need for immunosuppressant or anti-
TNF therapy and the benefit/risk and benefit/cost ratios 
would be unfavorable. In the second category, there is an 
intuition that there would be no advantage to wait before 
starting intensive therapy, while in the last third, the need 
for such treatment may presently be difficult to establish 
at the diagnosis or very early in the disease, and it is the 
disease evolution that will dictate the optimal strategy. 
The second group of patients is probably the most easy to 
identify as it corresponds to early severe presentation of 
the disease, including, in CD: extensive location, prob-
lematic location such as the rectum, abdominal and com-
plex perianal fistulizing lesions, multiple deep ulcers, and 
in UC: extensive severe colitis not rapidly controlled by 
mesalazine and/or oral steroid treatments. The first group 
of benign disease may be defined by localized and super-
ficial lesions, usually in older patients  [25] . The third 
group is composed of patients who do not meet the crite-
ria for the two other groups. In our opinion, this group 
should be closely monitored and the treatment gradually 
adapted before the tissue damage develops.
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 Should One Use Immunosuppressants and Anti-TNF 
as Monotherapy or Combination Therapy? 
 Several studies in rheumatic diseases and IBD have 
shown that a cotreatment with an immunosuppressant 
when using anti-TNF improved the pharmacokinetics of 
the anti-TNF and decreased the formation of anti-drug 
antibodies that may lead to allergic reaction and treat-
ment failure  [26, 27] . In CD, the SONIC trial has shown 
the superiority of anti-TNF therapy (monotherapy or 
combination therapy) over a treatment with purine ana-
logues both for achieving steroid-free remission and mu-
cosal healing  [28] . Furthermore, the data coming from 
long-term treatment with purine analogues and anti-
TNF do not seem to indicate a better safety with immu-
nosuppressants, particularly with purine analogues, as 
compared to anti-TNF. Hence, the main advantage of im-
munosuppressants may be their low cost. Another argu-
ment may be the good stability of the remission obtained 
with this type of drug, although this has never been ade-
quately assessed and particularly compared with the one 
obtained under anti-TNF. For these reasons, one may 
consider there is still indication for immunosuppressant 
monotherapy. This is even more the case in UC where the 
SUCCESS trial has not shown such a clear superiority of 
anti-TNF monotherapy over azathioprine monotherapy. 
The best candidate for immunosuppressant monothera-
py may be the steroid-dependent patient with moderate 
disease severity. One of the most consistent results of im-
munosuppressant therapy in IBD has been steroid spar-
ing and weaning.
 An even more controversial question is the one of the 
use of anti-TNF monotherapy. As highlighted above, in 
UC, this option does not seem to be strikingly superior to 
purine analogue monotherapy and should thus not be 
generally prescribed. In immunosuppressant-naïve CD 
patients, the SONIC trial has shown a clear superiority of 
anti-TNF monotherapy over immunosuppressant mono-
therapy, but also of immunosuppressant and anti-TNF 
combination therapy over anti-TNF monotherapy  [28] . 
Therefore, when an anti-TNF is prescribed early in the 
disease because of the initial severity of presentation, as 
defined in the previous paragraph, or steroid refractori-
ness, a combination therapy should probably be preferred 
to give the patient the highest chance of rapid disease con-
trol and limited tissue damage. This choice may be more 
debatable when an anti-TNF is prescribed in less severe 
patients either due to immunosuppressant intolerance or 
due to patient or physician preference not taking cost into 
account. The advantage of a combination therapy in pa-
tients having failed an immunosuppressant is less well
established. Post hoc analyses of individual trials with 
adalimumab or even infliximab have not shown a clear 
superiority of combination over monotherapy  [1, 2] . 
Nevertheless, retrospective analyses of cohorts of patients 
treated in referral centers have shown both for infliximab 
and adalimumab, a significant increase in treatment fail-
ure rate as well as an increase in the requirement for the 
use of higher dosage of anti-TNF in monotherapy  [29, 
30] . With adalimumab, this benefit on treatment failure 
rate was only significant for the first 6 months of therapy, 
while the reduction of the dosage of anti-TNF remained 
beyond 6 months. With infliximab, the IMID trial had 
already shown that the benefit of continuing immuno-
suppressants together with infliximab beyond 6 months 
of combination therapy was weak on clinical outcome, 
although trough levels of infliximab remained higher and 
level of C-reactive protein (CRP) lower in patients con-
tinuing their immunosuppressants  [31] . Overall, it seems 
that the benefit of a combination therapy may work 
through both synergistic effects and improved pharma-
cokinetics in immunosuppressant-naïve patients, while it 
may be mainly through improved pharmacokinetics in 
patients in whom immunosuppressant therapy has failed. 
Recently, the report of a small series of CD patients im-
proving their clinical situation together with an increase 
of trough levels and a disappearance of anti-drug anti-
bodies following the addition of an immunosuppressant 
to an anti-TNF monotherapy suggested the possibility of 
a more flexible use of these combination therapies de-
pending on patients’ clinical evolution  [32] .
 Is It Ever Possible to Stop Immunosuppressants or 
Anti-TNF? 
 Anti-TNF has now been used in clinical trials and rou-
tine practice for more than 15 years and immunosuppres-
sants for more than 30 years. They have been associated 
with long-term benefit including sustained clinical re-
mission, mucosal healing, healing of fistulas, decreased 
amount of hospitalizations, decreased amount of sur-
geries, increased quality of life and ability to work and 
perform daily activities. This has been associated with a 
reasonably good safety profile and globally a favorable 
benefit/risk ratio. The most striking risks are rare oppor-
tunistic infections, and lymphomas  [17, 18] .
 Despite this favorable benefit/risk ratio, reasons exist 
to contemplate anti-TNF or immunosuppressant with-
drawal in IBD patients. The main reasons are the fear of 






side effects, mild intolerance and wish of pregnancy. For 
anti-TNF, another important reason is the cost of thera-
py: anti-TNF have been shown to be potentially cost-ef-
fective for the treatment of IBD, but sensitivity analyses 
highlighted the fact that this cost-effectiveness was influ-
enced by treatment duration and that treating beyond 4 
years may not be cost-effective at classically admitted 
thresholds  [3–34] . Overall, the decision to stop or con-
tinue an anti-TNF therapy is thus a trade-off integrating 
all the above-mentioned considerations. However, para-
mount in this trade-off is the risk of disease progression 
and the risk of relapse upon treatment withdrawal as well 
as the possibility to retreat these relapsing patients. 
 A few data are available on this topic in UC. An Italian 
study showed that one third, one half and two thirds of 
patients relapsed after 1, 2 and 3 years of azathioprine 
withdrawal  [35] . The colectomy rate after azathioprine 
withdrawal was 10%; risk factors for colectomy includ-
ed absence of mesalazine treatment and short duration of 
azathioprine treatment. Only preliminary data from 
Hungary are available for anti-TNF  [36] . They suggest a 
relapse rate similar to the one described after azathio-
prine withdrawal. No predictor could be identified, and 
particularly mucosal healing at the time of withdrawal 
was not associated with a lower risk of relapse. 
 The data available on treatment withdrawal in CD are 
also limited. We may separately consider perianal fistuliz-
ing disease and luminal disease. For perianal disease, no 
prospective specific study of anti-TNF or immunosup-
pressant withdrawal has been performed, but retrospec-
tive analysis from experienced centers has suggested a 
high incidence of relapse  [37] . Along the same line, long-
term assessment of perianal CD continuously treated 
with anti-TNF showed persisting inflammatory fistulous 
tracks in a large proportion of them  [4–38] . For luminal 
CD, two prospective studies by the GETAID specifically 
focused on the risk of relapse after infliximab and aza-
thioprine discontinuation in patients being in stable re-
mission without steroids  [39, 5–40] . The study on aza-
thioprine withdrawal was placebo controlled and re-
vealed a relapse rate of 20% over 18 months as compared 
to 10% when continuing azathioprine. Long-term follow-
up of these patients revealed that up to two thirds of the 
patients relapsed over the next 5 years  [41] . Predictors of 
sustained remission included high hemoglobin level, low 
CRP and low white cell count. Retreatment with azathio-
prine was rapidly effective in almost all the patients. The 
study of anti-TNF withdrawal focused on patients treated 
by a combination therapy with infliximab and an immu-
nosuppressant for at least one year  [40] . This study re-
vealed a relapse rate over one year approaching 50%. Dis-
continuing anti-TNF is thus not a globally advisable strat-
egy, as the relapse rate in such kind of patients continuing 
their anti-TNF is probably below 10% per year. Neverthe-
less, this study also showed that patients could be strati-
fied according to their risk of relapse and that a subgroup 
of patients representing 25% of the whole cohort experi-
enced a more acceptable risk, around 10% per year. The 
factors associated with a low risk of relapse and that may 
help to select patients for such de-escalation strategy in-
cluded mucosal healing, normalized CRP, low fecal cal-
protectin and high hemoglobin levels. Another impor-
tant aspect of this study was that relapsing patients could 
be effectively and safely retreated by resuming infliximab 
scheduled treatment. Around 90% of them were in remis-
sion 2–4 months after resuming infliximab, and none of 
them developed infusion reaction or anti-infliximab an-
tibodies. This remission was also sustained over time and 
the secondary loss of response was around 6%/year with 
a median follow-up of 2 years.
 Overall, the preliminary results available indicate that 
there is a need for prospective studies assessing anti-TNF 
and immunosuppressant de-escalation strategies in IBD. 
The majority of patients seem to relapse over time and 
one cannot exclude disease progression in CD and a risk 
of colectomy in UC. Therefore, currently, in routine prac-
tice, such treatment withdrawal should be carefully dis-
cussed with the patients and only contemplated in pa-
tients in long-standing stable and deep remission, exten-
sively weighing and explaining to the patients potential 
benefits and risks of such withdrawal. Future studies 
should also determine if disease monitoring with bio-
markers, endoscopy and/or cross-sectional imaging may 
allow to promptly re-treat the patients, avoiding the con-
sequences of the relapse. 
 Conclusion 
 Immunosuppressants and anti-TNF are the corner-
stones of the treatment of moderate to severe CD and of 
UC failing steroids and mesalazine. Their introduction in 
the disease course should be tailored to the individual risk 
of disease progression, but should be early enough to 
avoid significant tissue damage. Today, the most effective 
treatment for both CD and UC seems to be a combination 
therapy with immunosuppressants and anti-TNF, al-
though this may be debated in patients with immunosup-
pressant failure and particularly beyond 6 months of 
combination therapy. Immunosuppressant or anti-TNF 
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withdrawal is generally associated with a high risk of re-
lapse. Nevertheless, in patients having achieved a state of 
long-standing and deep remission and in whom the risk 
of disease progression is considered to be low, this with-
drawal may be discussed with the patient putting in per-
spective benefits, cost and risks.
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